TY - JOUR
T1 - Preclinical models and technologies to advance nanovaccine development
AU - Peres, Carina
AU - Matos, Ana I.
AU - Moura, Liane I.F.
AU - Acúrcio, Rita C.
AU - Carreira, Barbara
AU - Pozzi, Sabina
AU - Vaskovich-Koubi, Daniella
AU - Kleiner, Ron
AU - Satchi-Fainaro, Ronit
AU - Florindo, Helena F.
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/5
Y1 - 2021/5
N2 - The remarkable success of targeted immunotherapies is revolutionizing cancer treatment. However, tumor heterogeneity and low immunogenicity, in addition to several tumor-associated immunosuppression mechanisms are among the major factors that have precluded the success of cancer vaccines as targeted cancer immunotherapies. The exciting outcomes obtained in patients upon the injection of tumor-specific antigens and adjuvants intratumorally, reinvigorated interest in the use of nanotechnology to foster the delivery of vaccines to address cancer unmet needs. Thus, bridging nano-based vaccine platform development and predicted clinical outcomes the selection of the proper preclinical model will be fundamental. Preclinical models have revealed promising outcomes for cancer vaccines. However, only few cases were associated with clinical responses. This review addresses the major challenges related to the translation of cancer nano-based vaccines to the clinic, discussing the requirements for ex vivo and in vivo models of cancer to ensure the translation of preclinical success to patients.
AB - The remarkable success of targeted immunotherapies is revolutionizing cancer treatment. However, tumor heterogeneity and low immunogenicity, in addition to several tumor-associated immunosuppression mechanisms are among the major factors that have precluded the success of cancer vaccines as targeted cancer immunotherapies. The exciting outcomes obtained in patients upon the injection of tumor-specific antigens and adjuvants intratumorally, reinvigorated interest in the use of nanotechnology to foster the delivery of vaccines to address cancer unmet needs. Thus, bridging nano-based vaccine platform development and predicted clinical outcomes the selection of the proper preclinical model will be fundamental. Preclinical models have revealed promising outcomes for cancer vaccines. However, only few cases were associated with clinical responses. This review addresses the major challenges related to the translation of cancer nano-based vaccines to the clinic, discussing the requirements for ex vivo and in vivo models of cancer to ensure the translation of preclinical success to patients.
KW - Cancer preclinical models
KW - Cancer vaccine
KW - Clinical translation
KW - Nanotechnology
KW - Tumor immune microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85102970689&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2021.03.001
DO - 10.1016/j.addr.2021.03.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 33711401
AN - SCOPUS:85102970689
SN - 0169-409X
VL - 172
SP - 148
EP - 182
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -
